Across TCGA pan-cancer cohorts, ADAMTSL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ADAMTSL2 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ADAMTSL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ADAMTSL2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where ADAMTSL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.790	0.405	<.001	36	view →
PDAC	DFS	Median	All	0.849	0.675	.006	21	view →
CCRCC	DFS	Quartile	All	0.801	1.000	.035	11	view →
LUAD	DFS	Tertile	II,III,IV	0.735	0.993	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ADAMTSL2 tumor-vs-normal RNA expression · all ADAMTSL2 data types